. Change in the eczema area and severity index (EASI) score before and after azathioprine treatment (mean treatment duration, 22.20±19.84 weeks). There was a 42% reduction in the EASI score from the baseline (p＜0.017). *Statistically significant difference compared with the baseline. (Fig. 2) . When azathioprine was insufficient in controlling flare-ups, the patients were prescribed with systemic steroid as a rescue drug. In our review, 40% (8 of 20) of the patients needed a rescue drug during the course of azathioprine treatment. After the discontinuation of azathioprine, 45% (9 of 20) of the patients were able to remain on a minimal disease status with only antihistamine, topical immunomodulators, or topical steroids. In this study, we observed that after an average of 22.20±19.84 weeks of azathioprine treatment, 55% (11 of 20) of the patients reported "excellent" outcome according to Investigator's Global Assessment of clinical response. Our result was comparable to the 60% remission rate achieved in a study group of 37 patients treated with azathioprine during an 18-year period 2 .
The decrease of EASI score in our study was higher than in previously reported placebo-controlled studies on azathioprine (26% 3 or 37% 4 reduction in severity). However, the improvement rate should take into consideration those who took rescue drugs. For the adverse effects, there were no hypersensitivity reactions. Also, regular monitoring of complete blood count and routine chemistry did not show noticeable results. Although we have treated patients tolerant to 100 mg/day azathioprine for an average period of 88 weeks, this study has major limitations as there is no control group. The absence of a control group can both over-and underestimate the judgment on the efficacy of azathioprine. Nevertheless, decrease in the EASI score and improvement in subjective symptoms should provide some credentials for the clinical efficacy of azathioprine in AD and raise a suggestion that it can be an appropriate candidate for adult Asian AD patients who cannot use or are not responsive to cyclosporine.
